Home / Radiopharmaceutical, Peptide Receptor Radionuclide Therapy (PRRT) / Lutetium (177Lu) vipivotide tetraxetan
Back to Search

Lutetium (177Lu) vipivotide tetraxetan – Uses, Dosage, and Brands in UAE

Brand Name: PLUVICTO
Strength: 1000 MBq/mL | Form: Solution for Injection or Infusion
Price in UAE: AED 214777.50
Available in UAE pharmacies

About Lutetium (177Lu) vipivotide tetraxetan

Class: | Radiopharmaceutical, Peptide Receptor Radionuclide Therapy (PRRT) Use: | Treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) with somatostatin receptor-positive tumors Adult dose: | 7.4 GBq (200 mCi) administered intravenously every 6 to 8 weeks, up to a maximum of 4 doses Pediatric dose: | Safety and efficacy have not been established in pediatric patients; not recommended for use in this population Side effects: | Nausea, fatigue, dry mouth

Drug Class

Radiopharmaceutical, Peptide Receptor Radionuclide Therapy (PRRT)

Uses & Indications

Treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) with somatostatin receptor-positive tumors

Storage Requirements

Store in a refrigerator at 2°C to 8°C (36°F to 46°F); protect from light; do not freeze

Manufacturer & Packaging

Manufacturer: ADVANCED ACCELERATOR APPLICATIONS USA, INC., United States of America

Package Size

1 Glass Vial

Price & Supplier

Price in UAE: AED 214777.50

Dosage Information

Adult Dose

7.4 GBq (200 mCi) administered intravenously every 6 to 8 weeks, up to a maximum of 4 doses

Pediatric Dose

Safety and efficacy have not been established in pediatric patients; not recommended for use in this population

Side Effects

Nausea, fatigue, dry mouth, diarrhea, vomiting, decreased appetite, and potential hematologic toxicities (e.g., thrombocytopenia, leukopenia)

Contraindications & Precautions

Hypersensitivity to lutetium (177Lu) vipivotide tetraxetan or any component of the formulation; pregnancy and breastfeeding

Important Warnings

Risk of myelosuppression, renal toxicity, and secondary malignancies; monitor blood counts and renal function; ensure appropriate patient selection based on somatostatin receptor positivity

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. The information presented here is specific to medicines available in UAE pharmacies and is regularly updated to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.

View All Radiopharmaceutical, Peptide Receptor Radionuclide Therapy (PRRT) Medicines Browse All Categories